Kailera Therapeutics surges 62.5% in Nasdaq debut after $625 million IPO
Kailera Therapeutics jumped 62.5% in its Nasdaq debut, as investors flooded a $625 million IPO tied to the obesity-drug race. The rally shows how hot GLP-1 stocks remain.
Investors rushed into Kailera Therapeutics on its first day of Nasdaq trading, sending the biotech’s shares up 62.5% to an opening price of $26 after the company sold 39.0625 million shares at $16 apiece in a $625 million IPO. The response underscored how aggressively Wall Street is chasing exposure to obesity and GLP-1 therapies, a market many analysts expect could eventually become a $150 billion annual opportunity.
Kailera’s debut immediately placed it among the most closely watched new life-science listings in years. The offering was described as the largest U.S. biotech IPO since Moderna’s $600 million deal in December 2018, a sign that investor appetite has returned for companies with credible shots at the weight-loss trade. That enthusiasm has been reinforced by strategic dealmaking, as buyers and public investors alike have shown a willingness to pay up for programs that could challenge Eli Lilly and Novo Nordisk.
The company’s lead asset is ribupatide, also known as KAI-9531, a once-weekly injectable GLP-1/GIP dual agonist now in global phase 3 trials. Kailera is also advancing KAI-7535, a once-daily small-molecule GLP-1 receptor agonist, along with KAI-9531-T, an oral version of ribupatide, and KAI-4729, an injectable GLP-1/GIP/glucagon tri-agonist. Even so, the biggest clinical readouts for the lead program are not expected until 2028, leaving the stock heavily dependent on sentiment in the obesity-drug sector and on the broader biotech market.
Kailera’s pipeline and its financing history explain why investors were willing to move so quickly. The company launched in October 2024 with a $400 million Series A and followed with a $600 million Series B in October 2025 led by Bain Capital Private Equity. It also said it secured exclusive rights in May 2024 to four metabolic-disease assets outside Greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd., giving the company a China-linked origin story that has helped set it apart from other obesity hopefuls.
Ron Renaud, Kailera’s president and chief executive, brings a track record that includes leadership roles at Cerevel Therapeutics and Translate Bio, along with time as a partner at Bain Capital Life Sciences. That pedigree, together with the size of the IPO and the early trading pop, has made Kailera a test case for whether public investors are buying science with long-dated potential or simply chasing the next obesity-market trade. The debut suggests the answer is both, and that capital remains eager to pay for a slice of the GLP-1 boom.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
